Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted) (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) recorded quarterly EPS (Weighted Average and Diluted) of -$0.37 in Q1 2026, down 32.14% quarter-over-quarter from -$0.28 in Q4 2025, and up 11.9% on a YoY basis from -$0.33 in Q1 2025.
Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.37 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 11.9% year-over-year to -$0.37; the TTM figure through Mar 2026 stood at -$1.48 (up 52.26% YoY), while the FY2025 annual figure was -$1.53, up 65.46% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.37 for Q1 2026 at Amylyx Pharmaceuticals, down from -$0.28 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.31 in Q2 2023 to a low of -$1.75 in Q1 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.53 across 5 years, with a median of -$0.46 in 2025.
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) soared 133.33% in 2023, then plunged 8850.0% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.62 in 2022, then soared by 111.29% to $0.07 in 2023, then tumbled by 871.43% to -$0.54 in 2024, then soared by 48.15% to -$0.28 in 2025, then plunged by 32.14% to -$0.37 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.37 (Q1 2026), -$0.28 (Q4 2025), and -$0.37 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | -0.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.37 |
| Dec 31, 2025 | -0.28 |
| Sep 30, 2025 | -0.37 |
| Jun 30, 2025 | -0.46 |
| Mar 31, 2025 | -0.42 |
| Dec 31, 2024 | -0.54 |
| Sep 30, 2024 | -1.07 |
| Jun 30, 2024 | -1.07 |
| Mar 31, 2024 | -1.75 |
| Dec 31, 2023 | 0.07 |
| Sep 30, 2023 | 0.30 |
| Jun 30, 2023 | 0.31 |
| Mar 31, 2023 | 0.02 |
| Dec 31, 2022 | -0.62 |
| Sep 30, 2022 | -0.92 |
| Jun 30, 2022 | -0.93 |
| Mar 31, 2022 | -0.93 |
| Dec 31, 2021 | -4.15 |
| Sep 30, 2021 | -3.42 |
| Jun 30, 2021 | -3.41 |